<hexML>
<head>
<title>Custom AveXis News Feed</title>
<description>Contains the last XXX releases</description>
<flastmod date='2021-02-24T08:52:47 CET'/>
</head>
<body>
<press_releases>
<press_release id='983500' joint_id='983500' language='en' type='5'>
<published date='2020-06-01T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Community Statement on the Global Managed Access Program for AVXS-101]]></headline>
<ingress><![CDATA[AveXis Community Statement on the Global Managed Access Program for AVXS-101]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/983500.xml'/>
</press_release>
<press_release id='942500' joint_id='942500' language='en' type='5'>
<published date='2020-04-21T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Community Statement on the Coronavirus Disease (COVID-19)]]></headline>
<ingress><![CDATA[AveXis Community Statement on the Coronavirus Disease (COVID-19)]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/942500.xml'/>
</press_release>
<press_release id='818500' joint_id='818500' language='en' type='5'>
<published date='2019-12-19T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Community Statement on Global Managed Access Program for AVXS-101]]></headline>
<ingress><![CDATA[AveXis Community Statement on Global Managed Access Program for AVXS-101]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/818500.xml'/>
</press_release>
<press_release id='691500' joint_id='691500' language='en' type='5'>
<published date='2019-08-14T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Statement on Changes to Senior Leadership Team]]></headline>
<ingress><![CDATA[AveXis Statement on Changes to Senior Leadership Team]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/691500.xml'/>
</press_release>
<press_release id='671500' joint_id='671500' language='en' type='5'>
<published date='2019-07-25T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)]]></headline>
<ingress><![CDATA[AveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/671500.xml'/>
</press_release>
<press_release id='223500' joint_id='223500' language='en' type='5'>
<published date='2018-05-03T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Reports First Quarter 2018 Financial and Operating Results]]></headline>
<ingress><![CDATA[AveXis Reports First Quarter 2018 Financial and Operating Results]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/223500.xml'/>
</press_release>
<press_release id='215500' joint_id='215500' language='en' type='5'>
<published date='2018-04-25T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3]]></headline>
<ingress><![CDATA[AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/215500.xml'/>
</press_release>
<press_release id='214500' joint_id='214500' language='en' type='5'>
<published date='2018-04-24T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology]]></headline>
<ingress><![CDATA[AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/214500.xml'/>
</press_release>
<press_release id='209500' joint_id='209500' language='en' type='5'>
<published date='2018-04-19T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology]]></headline>
<ingress><![CDATA[AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/209500.xml'/>
</press_release>
<press_release id='186500' joint_id='186500' language='en' type='5'>
<published date='2018-03-27T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1]]></headline>
<ingress><![CDATA[AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/186500.xml'/>
</press_release>
<press_release id='172500' joint_id='172500' language='en' type='5'>
<published date='2018-03-13T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Enters into Licensing Agreement with Genethon]]></headline>
<ingress><![CDATA[AveXis Enters into Licensing Agreement with Genethon]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/172500.xml'/>
</press_release>
<press_release id='158500' joint_id='158500' language='en' type='5'>
<published date='2018-02-27T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results]]></headline>
<ingress><![CDATA[AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/158500.xml'/>
</press_release>
<press_release id='151500' joint_id='151500' language='en' type='5'>
<published date='2018-02-20T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results]]></headline>
<ingress><![CDATA[AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/151500.xml'/>
</press_release>
<press_release id='130500' joint_id='130500' language='en' type='5'>
<published date='2018-01-30T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients]]></headline>
<ingress><![CDATA[AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/130500.xml'/>
</press_release>
<press_release id='122500' joint_id='122500' language='en' type='5'>
<published date='2018-01-22T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares]]></headline>
<ingress><![CDATA[AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/122500.xml'/>
</press_release>
<press_release id='116584' joint_id='116584' language='en' type='5'>
<published date='2018-01-16T14:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Announces Pricing of Public Offering of Common Stock]]></headline>
<ingress><![CDATA[AveXis Announces Pricing of Public Offering of Common Stock]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/116584.xml'/>
</press_release>
<press_release id='116542' joint_id='116542' language='en' type='5'>
<published date='2018-01-16T13:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Announces Proposed Public Offering of Common Stock]]></headline>
<ingress><![CDATA[AveXis Announces Proposed Public Offering of Common Stock]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/116542.xml'/>
</press_release>
<press_release id='116500' joint_id='116500' language='en' type='5'>
<published date='2018-01-16T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy]]></headline>
<ingress><![CDATA[AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/116500.xml'/>
</press_release>
<press_release id='108500' joint_id='108500' language='en' type='5'>
<published date='2018-01-08T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy]]></headline>
<ingress><![CDATA[REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/108500.xml'/>
</press_release>
<press_release id='104500' joint_id='104500' language='en' type='5'>
<published date='2018-01-04T12:00:00 CET'/>
<categories>
<category id='5' label='English' keywords='language'/>
<category id='2890' label='Product' keywords='newstag'/>
</categories>
<release_tags>
<keyword>Media Release</keyword>
<keyword>Reimagine Medicine</keyword>
<keyword>Living With Disease</keyword>
<keyword>Novartis Gene Therapies</keyword>
</release_tags>
<headline><![CDATA[AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1]]></headline>
<ingress><![CDATA[AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1]]></ingress>
<location href='https://mr-feed.novartis.com/avexis-media-releases/104500.xml'/>
</press_release>
</press_releases>
</body>
</hexML>
